Voranigo for other grade disease – pro
FDA has approved Voranigo (vorasidenib), an isocitrate dehydrogenase-1 and isocitrate dehydrogenase-2 inhibitor, for the treatment of adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection. he approval of Voranigo is supported by results from INDIGO (NCT04164901), a randomized, multicenter, double-blind, placebo-controlled trial.
The results of INDIGO were published in The New England Journal of Medicine and presented during the plenary session at the 2023 annual meeting of the American Society of Clinical Oncology. The trial showed that Voranigo significantly extended progression-free survival and time to next intervention, when compared to placebo.
However, NCCN recommends this drug also for grade 3 disease. As such, even specifically grade 3.
There is clinical evidence regarding the effectiveness of this drug for this indication as published in the authoritative, peer-reviewed medical and scientific literature.
Konteatis Z, Artin E, Nicolay B, Straley K, Padyana AK, Jin L, Chen Y, Narayaraswamy R, Tong S, Wang F, Zhou D, Cui D, Cai Z, Luo Z, Fang C, Tang H, Lv X, Nagaraja R, Yang H, Su SM, Sui Z, Dang L, Yen K, Popovici-Muller J, Codega P, Campos C, Mellinghoff IK, Biller SA. Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma. ACS Med Chem Lett. 2020 Jan 22;11(2):101-107
NCCN CNS Cancer 2024, GLIO-A, 2 of 9
Voranigo Prescribing Information 2024